| Similar Articles |
|---|
 |
The Motley Fool
December 10, 2010
Sean Williams |
ICU Medical: Bargain or Value Trap? International sales growth will be the key to the medical supplier's long-term success.   |
The Motley Fool
January 31, 2006
Stephen D. Simpson |
Guidance Puts ICU Medical in the Trauma Ward This oft-volatile stock had a strong fourth quarter, but weak guidance. Even with today's steep drop in price, the shares aren't cheap enough to be interesting. |
Pharmaceutical Executive
February 1, 2013
William Looney |
Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice. |
BusinessWeek
February 16, 2004
Catherine Arnst |
Medicare vs. Cancer Patients Refusing to reimburse off-label treatment is far from the best way to cut costs. |
The Motley Fool
July 22, 2009
Chris Jones |
Are These Winners Worth the Risk? Will medical device and supply stocks keep posting big gains? |
Pharmaceutical Executive
February 1, 2013
William Looney |
In Cancer, Process Drives Progress Today's most important public health story is the advance in our understanding of the biology of cancer. |
Chemistry World
June 22, 2011
Sarah Houlton |
US Approves Cancer Drugs Twice as Fast as Europe Cancer drugs are, on average, approved nearly twice as fast in the US than they are in Europe. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
BusinessWeek
January 30, 2006
Catherine Arnst |
Going Broke To Stay Alive Rising prices for cancer treatments are making patients - and doctors - balk. |
The Motley Fool
July 19, 2005
Stephen D. Simpson |
Peek-a-Boo ICU ICU Medical has taken on quite a bit of risk in the process of remaking the company. It's best to wait for a reasonable valuation before buying shares. |
Pharmaceutical Executive
August 1, 2012
Debbie Warner |
Adapting to a New Era of Cancer Care Coverage and treatment decisions will be driven by value and defined differently by each stakeholder. |
The Motley Fool
January 18, 2012
Sean Williams |
Are These 2 Medical Device Makers Takeover Targets? Could these two medical device makers put themselves up for sale in 2012? |
BusinessWeek
June 21, 2004
Catherine Arnst |
Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs. |
Nursing Management
December 2009
Rebecca J. Zapatochny Rufo |
Proven again... innovative integration of the virtual ICU in long-term care The virtual ICU allows a centralized intensivist-led care team to continuously monitor, assess, and intervene in support of on-site caregivers. |
BusinessWeek
June 16, 2011
Langreth & Cortez |
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. |
American Journal of Nursing
January 2010 |
Life-Support Interventions at the End of Life: Unintended Consequences Nurses need to be knowledgeable life-support interventions at the end of life and able to communicate what they know about those consequences to patients, family members, and others on the health care team, leading to better decision making at this difficult time. |
BusinessWeek
July 17, 2006
Bruce Einhorn |
A Key New Ally In The Cancer War China and its Western trade partners are fighting together on at least one front: the war on cancer. |
The Motley Fool
October 27, 2006
Jack Uldrich |
Nanotech and the War on Cancer New imaging advances in nanotechnology will help speed cancers' end. What does it mean for investors? |
Managed Care
August 2007
Martin Sipkoff |
Soaring Price of Cancer Drugs Leads Plans To New Approaches Insurers are trying different methods, from pay for performance to promoting preventive care, to hold down cost of chemotherapy drugs. |
BusinessWeek
June 26, 2006
Timothy J. Mullaney |
The Doctor Is (Plugged) In How remote patient monitoring lets fewer specialists provide more attentive care. |
Pharmaceutical Executive
July 3, 2007
Sarah Houlton |
Global Report: Five-Year Survivor: European Edition The UK government's attitude seems to be that oncology treatments are hugely expensive -- and that too much of the National Health Service budget is vanishing into the pockets of drug companies. Will cancer networks fill the gap? |
